Henlius Reshapes Global Licensing Strategy for HANSIZHUANG With Abbott and KGBio

Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an update.

Shanghai Henlius Biotech has restructured its regional licensing strategy for its anti-PD-1 therapy HANSIZHUANG by adjusting existing agreements with partners Abbott and PT Kalbe Genexine Biologics. The move consolidates rights across multiple emerging markets and aligns commercial responsibilities with larger-scale partners to support broader global rollout of the drug.

The company has partially terminated KGBio’s exclusive rights outside Indonesia, requiring KGBio to transfer marketing authorisations in those territories while Henlius pays up to US$33.75 million in milestones tied to the transfer. Henlius has simultaneously expanded Abbott’s licensed territory to cover 42 additional countries across Asia, the Middle East, Africa and Eastern Europe, with Abbott to pay up to US$126 million in new regulatory and sales milestones, reinforcing Henlius’s international commercialisation strategy for HANSIZHUANG.

The most recent analyst rating on (HK:2696) stock is a Hold with a HK$64.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.

More about Shanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. is a PRC-based biopharmaceutical company focused on developing and commercialising innovative biologic therapies. Its pipeline includes oncology products such as HANSIZHUANG (serplulimab injection), with a market focus on emerging regions including Asia, Latin America, the Middle East, Africa and Eastern Europe.

Average Trading Volume: 931,341

Technical Sentiment Signal: Buy

Current Market Cap: HK$51.19B

See more data about 2696 stock on TipRanks’ Stock Analysis page.